347 related articles for article (PubMed ID: 25158675)
1. G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues.
Cherry AE; Stella N
Neuroscience; 2014 Oct; 278():222-36. PubMed ID: 25158675
[TBL] [Abstract][Full Text] [Related]
2. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
3. Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme.
Tilak M; Holborn J; New LA; Lalonde J; Jones N
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673213
[TBL] [Abstract][Full Text] [Related]
4. G-protein-coupled receptors as therapeutic targets for glioblastoma.
Byrne KF; Pal A; Curtin JF; Stephens JC; Kinsella GK
Drug Discov Today; 2021 Dec; 26(12):2858-2870. PubMed ID: 34271165
[TBL] [Abstract][Full Text] [Related]
5. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
6. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
[TBL] [Abstract][Full Text] [Related]
7. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis.
Valter MM; Hügel A; Huang HJ; Cavenee WK; Wiestler OD; Pietsch T; Wernert N
Cancer Res; 1999 Nov; 59(21):5608-14. PubMed ID: 10554042
[TBL] [Abstract][Full Text] [Related]
8. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
Guo G; Narayan RN; Horton L; Patel TR; Habib AA
Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
10. Targeting malignant glioma survival signalling to improve clinical outcomes.
Wong ML; Kaye AH; Hovens CM
J Clin Neurosci; 2007 Apr; 14(4):301-8. PubMed ID: 17276069
[TBL] [Abstract][Full Text] [Related]
11. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; Inda MM; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14164-9. PubMed ID: 22891331
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme.
Tuncel G; Kalkan R
Med Oncol; 2018 Aug; 35(9):122. PubMed ID: 30078108
[TBL] [Abstract][Full Text] [Related]
13. Delivery systems and molecular targets of mechanism-based therapies for GBM.
Phuphanich S; Brat DJ; Olson JJ
Expert Rev Neurother; 2004 Jul; 4(4):649-63. PubMed ID: 15853584
[TBL] [Abstract][Full Text] [Related]
14. Network pharmacology of glioblastoma.
Aguda BD
Curr Drug Discov Technol; 2013 Jun; 10(2):125-38. PubMed ID: 23237675
[TBL] [Abstract][Full Text] [Related]
15. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
[TBL] [Abstract][Full Text] [Related]
16. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
17. The role of G-protein coupled receptors and associated proteins in receptor tyrosine kinase signal transduction.
Waters C; Pyne S; Pyne NJ
Semin Cell Dev Biol; 2004 Jun; 15(3):309-23. PubMed ID: 15125894
[TBL] [Abstract][Full Text] [Related]
18. Signal transduction pathways of G protein-coupled receptors and their cross-talk with receptor tyrosine kinases: lessons from bradykinin signaling.
Liebmann C; Böhmer FD
Curr Med Chem; 2000 Sep; 7(9):911-43. PubMed ID: 10911023
[TBL] [Abstract][Full Text] [Related]
19. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
Mao H; Lebrun DG; Yang J; Zhu VF; Li M
Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
[TBL] [Abstract][Full Text] [Related]
20. Transducing the signals: a G protein takes a new identity.
Dhanasekaran DN
Sci STKE; 2006 Aug; 2006(347):pe31. PubMed ID: 16896192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
